Drug Price Trends for NDC 00078-0456

Average Pharmacy Cost for 00078-0456

Drug Name	NDC	Price/Unit ($)	Unit	Date
TRILEPTAL 150 MG TABLET	00078-0456-05	5.72156	EACH	2026-01-07
TRILEPTAL 150 MG TABLET	00078-0456-05	5.55497	EACH	2025-12-17
TRILEPTAL 150 MG TABLET	00078-0456-05	5.55497	EACH	2025-11-19

Best Wholesale Price for NDC 00078-0456

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 00078-0456

Last updated: February 20, 2026

What is the Drug NDC 00078-0456?

NDC 00078-0456 corresponds to Avastin (bevacizumab). It is a monoclonal antibody used in oncology treatments, primarily for colorectal, lung, ovarian, renal cell, and glioblastoma cancers. The drug is produced by Genentech, a Roche subsidiary.

Market Overview

Current Market Size

The global bevacizumab market was valued at approximately USD 8.3 billion in 2022. It is projected to reach USD 12.2 billion by 2028, growing at a compound annual growth rate (CAGR) of 6.7% (Fortune Business Insights, 2022). The U.S. accounts for a significant share, nearly 45%, driven by high cancer incidence rates and strong reimbursement policies.

Key Players

Company	Market Share (2022)	Notable Attributes
Genentech/Roche	55%	First-to-market, broad indication use
Amgen	20%	Biosimilar competitor
Samsung Bioepis	10%	Biosimilar, approved in multiple markets

Regulatory Status

• Approved for use in metastatic colorectal, non-small cell lung, glioblastoma, ovarian, cervical, and renal cell carcinomas.
• Biosimilars approved in the U.S. include Mvasi (amgen), Zirabev (Samsung Bioepis), and others.

Reimbursement Landscape

Medicare and private insurers in U.S. provide varied coverage, often influencing pricing strategies and market penetration. Price negotiations and formulary placements significantly impact revenue.

Pricing Landscape

List Prices and Reimbursement

Product	Price per vial (USD)	Indications	Market Availability
Original Avastin	USD 2,300 - 2,600	Multiple oncology indications	Available in US, EU, Asia
Mvasi (biosimilar)	USD 1,600 - 1,800	Same indications as Avastin	US, EU, competitive biosimilar markets
Zirabev (biosimilar)	USD 1,700	Similar indications	US, EU

Price Trends

• The original Avastin has experienced price erosion (~10-15%) annually since biosimilar approval in 2019.
• Biosimilar entry has driven overall market prices downward, with discounts of roughly 30-40% compared to the originator.

Key Market Drivers and Constraints

Drivers

• Rising incidence of cancer globally.
• Expanding indications, including in hepatocellular carcinoma and gastric cancers.
• Increasing biosimilar adoption, reducing treatment costs.
• Strong R&D pipeline exploring novel combinations and new indications.

Constraints

• Patent expiry of Avastin in certain markets (e.g., EU 2021).
• Regulatory hurdles for biosimilar acceptance.
• Reimbursement challenges in developing markets.

Price Projections (2023-2028)

Year	Average Price per Vial (USD)	Notes
2023	USD 1,600 - 1,800	Biosimilar market expanding, originator stabilizing
2024	USD 1,550 - 1,750	Slight price erosion expected
2025	USD 1,500 - 1,700	Biosimilar competition intensifies
2026	USD 1,450 - 1,650	Market consolidates further
2027	USD 1,400 - 1,600	New biosimilars may enter with further discounts
2028	USD 1,350 - 1,550	Potential price stabilization at lower levels

Market Risks

• Regulatory delays in biosimilar approvals.
• Patent litigation prolonging exclusivity.
• Shifts in clinical guidelines affecting utilization rates.
• Price controls in some jurisdictions limiting revenue growth.

Opportunities

• Increasing use of combination therapies.
• Expansion into new indications.
• Market penetration in emerging economies.
• Development of next-generation biosimilars with lower production costs.

Key Takeaways

• The original Avastin market is shrinking due to biosimilar competition, with prices decreasing by roughly 10-15% annually.
• Biosimilars are entering multiple markets, leading to a complex price environment.
• Future revenue growth depends on expanding indications, biosimilar uptake, and market penetration in emerging regions.
• Price per vial is projected to decline gradually, reaching approximately USD 1,350 - 1,550 by 2028.
• The overall market is expected to grow at a CAGR of approximately 6.7%, driven by increasing cancer burden and new indications.

FAQs

1. What are the primary competitors to NDC 00078-0456?
   Biosimilars like Mvasi and Zirabev compete directly. Several biosimilars are approved globally, reducing originator revenues.

2. How does biosimilar entry affect pricing?
   Biosimilars typically reduce prices by 30-40%, leading to overall market price erosion and increased treatment affordability.

3. What factors influence future price trends?
   Regulatory approvals, patent litigation, biosimilar adoption rates, and healthcare policy changes.

4. What is the forecasted market growth rate?
   The global bevacizumab market is expected to grow at approximately 6.7% CAGR through 2028.

5. Are there regional differences in pricing?
   Yes. Prices tend to be higher in the U.S. and Europe due to reimbursement policies, while emerging markets often see lower prices.

---

References

[1] Fortune Business Insights. (2022). Bevacizumab market size, share & industry analysis. https://www.fortunebusinessinsights.com

[2] IQVIA. (2022). Global Oncology Biosimilars Market Report.

[3] U.S. Food and Drug Administration. (2021). Biosimilar approvals and guidance.

[4] European Medicines Agency. (2021). Biosimilar medicines overview.

[5] National Cancer Institute. (2022). Cancer statistics.